A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients

A proof-of-concept study on the genomic evolution of SARS-CoV-2 during antiviral treatment reveals that Molnupiravir induces a higher in vivo intra-host variability compared to Paxlovid and drug-naive.

Bibliographic Details
Main Authors:	Claudia Alteri, Valeria Fox, Rossana Scutari, Giulia Jole Burastero, Sara Volpi, Matteo Faltoni, Vanessa Fini, Annarita Granaglia, Sara Esperti, Altea Gallerani, Valentino Costabile, Beatrice Fontana, Erica Franceschini, Marianna Meschiari, Andrea Campana, Stefania Bernardi, Alberto Villani, Paola Bernaschi, Cristina Russo, Giovanni Guaraldi, Cristina Mussini, Carlo Federico Perno
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-12-01
Series:	Communications Biology
Online Access:	https://doi.org/10.1038/s42003-022-04322-8

Similar Items

A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia
by: Rossana Scutari, et al.
Published: (2023-03-01)

Is It Possible to Eradicate Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) from Endemic Hospitals?
by: Filippo Medioli, et al.
Published: (2022-07-01)

Population-Based Propensity Score-Matched Analysis of Paxlovid and Molnupiravir Effectiveness in High-Risk COVID-19 Patients
by: Dr Yi-hsuan Chen, et al.
Published: (2025-03-01)

Epidemiology and Prevention of Early Infections by Multi-Drug-Resistant Organisms in Adults Undergoing Liver Transplant: A Narrative Review
by: Giovanni Dolci, et al.
Published: (2023-06-01)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
by: Wen Wen, et al.
Published: (2022-12-01)

Molnupiravir; an effective drug in treating COVID-19?
by: Alireza Pouramini, et al.
Published: (2022-01-01)

D-dimer for efficacy prediction in COVID-19 patients treated with paxlovid
by: Daishi Li, et al.
Published: (2024-11-01)

Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders
by: Ting-Hui Liu, et al.
Published: (2024-07-01)

The Path to Paxlovid
by: Bethany Halford
Published: (2022-04-01)

Molecular characterization of SARS-CoV-2 Omicron clade and clinical presentation in children
by: Rossana Scutari, et al.
Published: (2024-03-01)

Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature
by: Giulia Jole Burastero, et al.
Published: (2022-07-01)

Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib
by: Vanyo Mitev
Published: (2023-10-01)

28 Experiences of using Paxlovid to treat clinically extremely vulnerable non-hospitalised patients with COVID-19
by: Joshua Gahir, et al.
Published: (2022-09-01)

Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patients
by: Aaisha Shah, et al.
Published: (2022-09-01)

Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome coronavirus 2 in pediatric and adult patients
by: Luna Colagrossi, et al.
Published: (2022-11-01)

A rare case of necrotizing fasciitis of the leg in an intravenous drug user caused by Prevotella denticola
by: Andrea Bedini, et al.
Published: (2024-12-01)

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice
by: Dagmara Mirowska-Guzel, et al.
Published: (2023-09-01)

Publisher Correction: Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation
by: Claudia Alteri, et al.
Published: (2022-07-01)

Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation
by: Claudia Alteri, et al.
Published: (2022-06-01)

Sustainable and technically smart spectrophotometric determination of PAXLOVID: a comprehensive ecological and analytical performance rating
by: Sara I. Aboras, et al.
Published: (2024-09-01)

Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China
by: Yang W, et al.
Published: (2024-03-01)

Activation of PXR causes drug interactions with Paxlovid in transgenic mice
by: Saifei Lei, et al.
Published: (2023-11-01)

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections
by: Altea Gallerani, et al.
Published: (2023-11-01)

Molnupiravir: From Hope to Epic Fail?
by: Daniele Focosi
Published: (2022-11-01)

Why Molnupiravir Fails in Hospitalized Patients
by: Ashley N. Brown, et al.
Published: (2022-12-01)

Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study
by: Ye Qiu, et al.
Published: (2024-08-01)

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors
by: Rossana Scutari, et al.
Published: (2020-03-01)

Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study
by: Qinyue Zheng, et al.
Published: (2023-04-01)

A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19
by: Keisuke Nakamura, et al.
Published: (2022-11-01)

Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight
by: Giang H. Ta, et al.
Published: (2024-11-01)

An Investigation of Nirmatrelvir (Paxlovid) Resistance in SARS-CoV‑2 Mpro
by: Rasha M. Yaghi, et al.
Published: (2024-10-01)

Clinical characteristics and pharmacokinetics of PAXLOVID in COVID-19 patients with hematological tumor
by: Liu Wei, et al.
Published: (2024-04-01)

Public Health Impact of Paxlovid as Treatment for COVID-19, United States
by: Yuan Bai, et al.
Published: (2024-02-01)

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients
by: Peng Su, et al.
Published: (2024-01-01)

A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH
by: Sarah Mohamed, et al.
Published: (2023-09-01)

Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China
by: Weina Zhang, et al.
Published: (2023-06-01)

REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
by: P. Periyasamy, et al.
Published: (2023-05-01)

Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor
by: Alireza Pouramini, et al.
Published: (2022-07-01)

Safety and Efficacy of Paxlovid in COVID-19 Treatment: A Rapid Review
by: Mohamad Reza Mobinizadeh, et al.
Published: (2022-10-01)

BIOEQUIVALENCE STUDY OF GENERIC MOLNUPIRAVIR IN HEALTHY VOLUNTEERS
by: V. B. Vasilyuk, et al.
Published: (2023-02-01)